The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future
Open accessAbstract
The evolution of human immunodeficiency virus (HIV) treatment has improved our understanding and management of complex pharmacological issues that have driven improved outcomes and quality of life of the HIV‐infected patient. These issues include adherence, long‐ and short‐term toxicities, pharmacoenhancement, pharmacogenomics, therapeutic drug monitoring, differential penetration of drugs into sanctuary sites, such as the central nervous system, genital tract and small bowel, and drug–drug and drug–food interactions related to cytochrome P 450 drug‐metabolizing enzymes, uridine diphosphate glucuronyltransferases and drug transporters, to name a few. There is future promise, as an increased understanding of the immunopathogenesis of HIV and global public health initiatives are driving novel treatment approaches with goals to prevent, control and, ultimately, eradicate HIV.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,405
Prevention of HIV-1 infection with early antiretroviral therapy.
Cohen, M. S., Chen, Y. Q., McCauley, M., Gamble, T., Hosseinipour, M. C., Kumarasamy, N., Hakim, J. G., Kumwenda, J., Grinsztejn, B., Pilotto, J. H. S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105243 · Cited by 6,873
Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection
Paterson, D. L., Swindells, S., Mohr, J., Brester, M., Vergis, E. N., Squier, C., Wagener, M. M., & Singh, N. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-1-200007040-00004 · Cited by 3,289
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., Campbell, J. D., Wangisi, J., Tappero, J. W., Bukusi, E. A., Cohen, C. R., Katabira, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108524 · Cited by 3,256
The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex
Fischl, M. A., Richman, D. D., Grieco, M. H., Gottlieb, M. S., Volberding, P. A., Laskin, O. L., Leedom, J. M., Groopman, J. E., Mildvan, D., Schooley, R. T., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198707233170401 · Cited by 2,995
CD4+ Count–Guided Interruption of Antiretroviral Treatment
(2006) · New England Journal of Medicine · doi:10.1056/nejmoa062360 · Cited by 2,231
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Thigpen, M. C., Kebaabetswe, P. M., Paxton, L. A., Smith, D. K., Rose, C. E., Segolodi, T. M., Henderson, F. L., Pathak, S. R., Soud, F. A., Chillag, K. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110711 · Cited by 1,996
Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation
Hütter, G., Nowak, D., Mossner, M., Ganepola, S., Müßig, A., Allers, K., Schneider, T., Hofmann, J., Kücherer, C., Blau, O., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0802905 · Cited by 1,837
HLA-B*5701 Screening for Hypersensitivity to Abacavir
Mallal, S., Phillips, E., Carosi, G., Molina, J.-M., Workman, C., Tomažič, J., Jägel-Guedes, E., Rugina, S., Kozyrev, O., Cid, J. F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706135 · Cited by 1,835
Self-citationPreexposure Prophylaxis for HIV Infection among African Women
Van Damme, L., Corneli, A., Ahmed, K., Agot, K., Lombaard, J., Kapiga, S., Malahleha, M., Owino, F., Manongi, R., Onyango, J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202614 · Cited by 1,603
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
Archin, N. M., Liberty, A. L., Kashuba, A. D., Choudhary, S. K., Kuruc, J. D., Crooks, A. M., Parker, D. C., Anderson, E. M., Kearney, M. F., Strain, M. C., et al. (2012) · Nature · doi:10.1038/nature11286 · Cited by 1,139
Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival
Kitahata, M. M., Gange, S. J., Abraham, A. G., Merriman, B., Saag, M. S., Justice, A. C., Hogg, R. S., Deeks, S. G., Eron, J. J., Brooks, J. T., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0807252 · Cited by 1,105
Gazzard, B., & on behalf of the BHIVA Treatment Guidelines Writing Group (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2008.00636.x · Cited by 1,089
Indinavir concentrations and St John's wort
Piscitelli, S. C., Burstein, A. H., Chaitt, D., Alfaro, R. M., & Falloon, J. (2000) · The Lancet · doi:10.1016/s0140-6736(99)05712-8 · Cited by 874
The State of Engagement in HIV Care in the United States: From Cascade to Continuum to Control
Mugavero, M. J., Amico, K. R., Horn, T., & Thompson, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit420 · Cited by 508
Time to Hit HIV, Early and Hard
Ho, D. D. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508173330710 · Cited by 431
Hetherington, S., McGuirk, S., Powell, G., Cutrell, A., Naderer, O., Spreen, B., Lafon, S., Pearce, G., & Steel, H. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80132-6 · Cited by 406
Nachega, J. B., Parienti, J.-J., Uthman, O. A., Gross, R., Dowdy, D. W., Sax, P. E., Gallant, J. E., Mugavero, M. J., Mills, E. J., & Giordano, T. P. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu046 · Cited by 357
Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance
Wensing, A. M. J., van Maarseveen, N. M., & Nijhuis, M. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2009.10.003 · Cited by 339
Eron, J. J., Young, B., Cooper, D. A., Youle, M., DeJesus, E., Andrade-Villanueva, J., Workman, C., Zajdenverg, R., Fätkenheuer, G., Berger, D. S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62041-9 · Cited by 317
Zeldin, R. K. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh029 · Cited by 316
Rauch, A., Nolan, D., Martin, A., McKinnon, E., Almeida, C., & Mallal, S. (2006) · Clinical Infectious Diseases · doi:10.1086/504874 · Cited by 296
Yukl, S. A., Boritz, E., Busch, M., Bentsen, C., Chun, T.-W., Douek, D., Eisele, E., Haase, A., Ho, Y.-C., Hütter, G., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003347 · Cited by 291
Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1
Kowdley, K. V., Lawitz, E., Poordad, F., Cohen, D. E., Nelson, D. R., Zeuzem, S., Everson, G. T., Kwo, P., Foster, G. R., Sulkowski, M. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1306227 · Cited by 255
Long-acting injectable antiretrovirals for HIV treatment and prevention
Spreen, W. R., Margolis, D. A., & Pottage, J. C. (2013) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000002 · Cited by 246
Gatanaga, H., Hayashida, T., Tsuchiya, K., Yoshino, M., Kuwahara, T., Tsukada, H., Fujimoto, K., Sato, I., Ueda, M., Horiba, M., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/522175 · Cited by 223
Kempf, D. J., King, M. S., Bernstein, B., Cernohous, P., Bauer, E., Moseley, J., Gu, K., Hsu, A., Brun, S., & Sun, E. (2004) · The Journal of Infectious Diseases · doi:10.1086/380509 · Cited by 217
The Mind Exchange Working Group, Antinori, A., Arendt, G., Grant, I., Letendre, S., Chair, Munoz-Moreno, J. A., Eggers, C., Brew, B., Brouillette, M.-J., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cis975 · Cited by 208
Sax, P. E., Zolopa, A., Brar, I., Elion, R., Ortiz, R., Post, F., Wang, H., Callebaut, C., Martin, H., Fordyce, M. W., et al. (2014) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000225 · Cited by 207
Mathias, A. A., German, P., Murray, B. P., Wei, L., Jain, A., West, S., Warren, D., Hui, J., & Kearney, B. P. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.228 · Cited by 205
Martinez, E., Larrousse, M., Llibre, J. M., Gutierrez, F., Saumoy, M., Antela, A., Knobel, H., Murillas, J., Berenguer, J., Pich, J., et al. (2010) · AIDS · doi:10.1097/qad.0b013e32833a608a · Cited by 193
Drug hypersensitivity: Pharmacogenetics and clinical syndromes
Phillips, E. J., Chung, W.-H., Mockenhaupt, M., Roujeau, J.-C., & Mallal, S. A. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.11.046 · Cited by 178
Self-citationHIV drug resistance: problems and perspectives
Pennings, P. S. (2013) · Infectious Disease Reports · doi:10.4081/idr.2013.s1.e5 · Cited by 178
Foisy, M., Yakiwchuk, E., Chiu, I., & Singh, A. (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2008.00579.x · Cited by 174
Ageing with HIV: medication use and risk for potential drug-drug interactions
Marzolini, C., Back, D., Weber, R., Furrer, H., Cavassini, M., Calmy, A., Vernazza, P., Bernasconi, E., Khoo, S., Battegay, M., et al. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr248 · Cited by 163
Fatal interaction between ritonavir and MDMA
Henry, J., & Hill, I. R. (1998) · The Lancet · doi:10.1016/s0140-6736(05)79824-x · Cited by 143
Cost-Effectiveness of HIV Treatment as Prevention in Serodiscordant Couples
Walensky, R. P., Ross, E. L., Kumarasamy, N., Wood, R., Noubary, F., Paltiel, A. D., Nakamura, Y., Godbole, S., Panchia, R., Sanne, I., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmsa1214720 · Cited by 140
Tseng, A. L.-I., Szadkowski, L., Walmsley, S. L., Salit, I. E., & Raboud, J. (2013) · Annals of Pharmacotherapy · doi:10.1177/1060028013504075 · Cited by 111
Self-citationLubomirov, R., Colombo, S. F., di Iulio, J., Ledergerber, B., Martínez, R., Cavassini, M. L., Hirschel, B. J., Bernasconi, E., Elzi, L., Vernazza, P., et al. (2010) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiq043 · Cited by 100
Intravaginal rings as delivery systems for microbicides and multipurpose prevention technologies
Thurman, A. R., Clark, M. R., Hurlburt, J., & Doncel, G. F. (2013) · International Journal of Women s Health · doi:10.2147/ijwh.s34030 · Cited by 96
Deeks, E. D. (2013) · Drugs · doi:10.1007/s40265-013-0160-x · Cited by 95
Clinical Management of HIV Drug Resistance
Cortez, K. J., & Maldarelli, F. M. (2011) · Viruses · doi:10.3390/v3040347 · Cited by 78
The search for an HIV cure: tackling latent infection
Kent, S. J., Reece, J. C., Petravic, J., Martyushev, A., Kramski, M., Rose, R. D., Cooper, D. A., Kelleher, A. D., Emery, S., Cameron, P. U., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70043-4 · Cited by 72
Gandhi, R. T., Bosch, R. J., Aga, E., Albrecht, M., Demeter, L. M., Dykes, C., Bastow, B., Para, M. F., Lai, J., Siliciano, R. F., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/649569 · Cited by 71
Vassallo, M., Durant, J., Biscay, V., Lebrun‐Frénay, C., Dunais, B., Laffon, M., Harvey-Langton, A., Cottalorda, J., Ticchioni, M., Carsenti, H., et al. (2013) · AIDS · doi:10.1097/qad.0000000000000096 · Cited by 70
Tseng, A. L.-I., & Foisy, M. (2011) · Current Infectious Disease Reports · doi:10.1007/s11908-011-0229-1 · Cited by 55
Self-citationAssessment of topical microbicides to prevent HIV-1 transmission: Concepts, testing, lessons learned
Friend, D. R., & Kiser, P. F. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.06.021 · Cited by 48
Adherence to Anti-Retroviral Therapy and Its Determinants in HIV/AIDS Patients: A Review
Emamzadehfard, S., Fard, S. E., SeyedAlinaghi, S., & Paydary, K. (2012) · Infectious Disorders - Drug Targets · doi:10.2174/187152612804142251 · Cited by 45
Nanomedicines for Treatment of Viral Diseases
Mehendale, R., Joshi, M. D., & Patravale, V. B. (2013) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.2013005469 · Cited by 41
Crawford, K. W., Ripin, D. H. B., Levin, A. D., Campbell, J. R., & Flexner, C. W. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(12)70134-2 · Cited by 41
Antiretroviral-Based HIV-1 Prevention: Antiretroviral Treatment and Pre-Exposure Prophylaxis
Celum, C., & Baeten, J. M. (2012) · Antiviral Therapy · doi:10.3851/imp2492 · Cited by 37
Romano, J., Kashuba, A. D. M., Becker, S. L., Cummins, J. E., Turpin, J. A., & Veronese, O. B. O. T. A. F. (2013) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2013.0122 · Cited by 30
Hyle, E. P., Wood, B. R., Backman, E. S., Noubary, F., Hwang, J. J., Lu, Z., Losina, E., Walensky, R. P., & Gandhi, R. T. (2013) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31829b662b · Cited by 30
Sokal, D. C., Karim, Q. A., Sibeko, S., Yende‐Zuma, N., Mansoor, L. E., Baxter, C., Grobler, A. C., Frolich, J., Kharsany, A. B. M., Miya, N., et al. (2012) · Antiviral Therapy · doi:10.3851/imp2311 · Cited by 28
Xu, L., Liu, H., Hong, A. Y., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.12.057 · Cited by 25
Coumi, N., Guddera, V., & Investigator, S. (2009) · Cited by 16
Chen, J., Han, X., An, M., Liu, J., Xu, J., Geng, W., Ji, Y., & Shang, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082461 · Cited by 6
Cited by
Trickey, A., Sabin, C. A., Burkholder, G., Crane, H., d'Arminio Monforte, A., Egger, M., Gill, M. J., Grabar, S., Guest, J. L., Jarrin, I., et al. (2023) · The Lancet HIV · doi:10.1016/s2352-3018(23)00028-0 · Cited by 529
Joshi, S., Muwonge, R., Kulkarni, V., Mandolkar, M., Lucas, E., Pujari, S., Sankaranarayanan, R., & Basu, P. (2023) · International Journal of Cancer · doi:10.1002/ijc.34221 · Cited by 12
Lanièce Delaunay, C., Klein, M. B., Godin, A., Cox, J., Kronfli, N., Lebouché, B., Doyle, C., & Maheu-Giroux, M. (2023) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2023.104026 · Cited by 9
Metadata
- Authors
- Tseng, A., Seet, J., & Phillips, E. J.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2015-01-20
- Volume
- 79
- Issue
- 2
- Pages
- 182-194
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W1552317649
- Cited by
- 256
- References
- 57
- FWCI
- 4.54
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.